July 1, 2019
Affimed’s approach to advancing immuno-oncology
With our differentiated approach to arming the body’s innate immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.
Affimed (NASDAQ: AFMD) pioneers immune cell engagement, employing its insights and scientific expertise to harness the body’s innate immune systems in the fight against cancer and other life-threatening diseases. Our proprietary ROCK® (Redirected Optimized Cell Killing) platform allows for the modular design of tetravalent bi- and multi-specific antibodies, including first-in-class innate and adaptive cell engager products.
We are actualizing the next advancement in immuno-oncology (I-O) through our proprietary ROCK® platform, which stands for Redirected Optimized Cell Killing. Our new approach to build ROCK® based innate cell engagers aims to treat a broad range of hematologic and solid tumors by countering tumor immune evasion through activating a patient’s own innate immune system.
Our ROCK® platform-designed tetravalent bispecific innate cell engagers are being studied in a number of clinical and preclinical programs. These innate cell engagers are the first to demonstrate a favorable safety profile and promising signs of therapeutic efficacy.
Innate Cell Engagers